Cargando…

Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis

PURPOSE: Secondary hyperparathyroidism (SHPT) is one of the most common abnormalities of mineral metabolism in patients with chronic kidney disease. We performed a meta-analysis to determine the effect and safety of cinacalcet in SHPT patients receiving dialysis. METHODS: The meta-analysis was perfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qian, Li, Ming, You, Li, Li, Haiming, Ni, Li, Gu, Yong, Hao, Chuanming, Chen, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485048/ https://www.ncbi.nlm.nih.gov/pubmed/23133549 http://dx.doi.org/10.1371/journal.pone.0048070

Ejemplares similares

Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
por: Cunningham, John, et al.
Publicado: (2008)

Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy
por: Frazão, João, et al.
Publicado: (2008)

Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism
por: van der Plas, Willemijn Y., et al.
Publicado: (2016)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
por: Yu, Longchuan, et al.
Publicado: (2017)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
por: Pereira, Luciano, et al.
Publicado: (2018)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease
por: Konstantinidis, Ioannis, et al.
Publicado: (2013)

Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting
por: Perrone, Valentina, et al.
Publicado: (2022)

Relationship between patients’ characteristics and efficacy of calcimimetics for primary hyperparathyroidism in the elderly
por: Yamamoto, Koichiro, et al.
Publicado: (2022)

The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism
por: Khalpey, Zain, et al.
Publicado: (2010)

ODP102 Indicators for the effects of calcimimetics on hypercalcemia in the elderly patients with primary hyperparathyroidism.
por: Yamamoto, Koichro, et al.
Publicado: (2022)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis
por: Sun, Yiting, et al.
Publicado: (2020)

A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
por: Ohya, Yuichiro, et al.
Publicado: (2018)

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
por: Wetmore, James B, et al.
Publicado: (2008)

Real-world evidence and optimization of vocal dysfunction in end-stage renal disease patients with secondary hyperparathyroidism
por: Chang, Geng-He, et al.
Publicado: (2021)

Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study
por: Mima, Akira, et al.
Publicado: (2018)

Clinical study on the status of transient thyrotoxicosis after surgery for secondary hyperparathyroidism patients with end-stage renal disease and normal thyroid function
por: Zou, Bao-shan, et al.
Publicado: (2020)

A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug
por: Leunbach, T.L., et al.
Publicado: (2021)

Calcimimetics and outcomes in CKD
por: Drüeke, Tilman B
Publicado: (2013)

Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era
por: Conzo, Giovanni, et al.
Publicado: (2013)

Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism
por: Fang, Li, et al.
Publicado: (2018)

The calcimimetic R-568 induces apoptotic cell death in prostate cancer cells
por: Li, Huaifu, et al.
Publicado: (2009)

Novel Use of Calcimimetic Activity to Diagnose Primary Hyperparathyroidism in a Patient With Persistently Low-Normal Parathyroid Hormone Level
por: Bandaru, Sindhura, et al.
Publicado: (2020)

Effect of Pretransplant Use of Calcimimetic on Parathyroid Function after Renal Transplantation
por: Bokuda, Kanako, et al.
Publicado: (2021)

The association of secondary hyperparathyroidism and myocardial damages in hemodialysis end-stage renal disease patients: assessed by cardiovascular magnetic resonance native T1 mapping
por: Xu, Huayan, et al.
Publicado: (2021)

Brown Tumor as a Result of Hyperparathyroidism in an End-Stage Renal Disease Patient
por: Jakubowski, Jesse M., et al.
Publicado: (2011)

Reoperation for persistent or recurrent secondary hyperparathyroidism. Surgical treatment of renal hyperparathyroidism
por: Abruzzo, Alida, et al.
Publicado: (2017)

Osteitis Fibrosa Cystica; A Forgotten Manifestation of Secondary Hyperparathyroidism Due to End-Stage Renal Disease: A Case Report
por: Usmael, Semir Abdi, et al.
Publicado: (2022)

Coexisting Tertiary Hyperparathyroidism and Severe Hypothyroidism in an End-Stage Renal Disease Patient on Hemodialysis
por: Osman Malik, Yahya, et al.
Publicado: (2015)

Parathyroidectomy Versus Calcimimetic: The Lower the PTH the Better?
por: Evenepoel, Pieter, et al.
Publicado: (2022)

Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: A case-control study
por: Sliem, Hamdy, et al.
Publicado: (2011)

Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end-stage renal disease: A case control study
por: Sliem, Hamdy, et al.
Publicado: (2011)

Persistent Calciphylaxis and Secondary Hyperparathyroidism in End Stage Renal Disease Patient Due to Ectopic Mediastinal Parathyroid Adenoma- A Case Report
por: Abdelmasih, Randa, et al.
Publicado: (2021)

Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
por: Törmänen, Suvi, et al.
Publicado: (2017)

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients
por: Fukagawa, Masafumi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ok8oosq5dordi2evvhnfr8d01i